Both are available through InjectCo's physician-supervised BriteBody program
According to NICE NG28 guidance: First-line therapy for most people includes metformin (if tolerated) alongside lifestyle modifications SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) may be considered first line for people with established cardiovascular disease, high cardiovascular risk, or chronic kidney disease, offering cardiovascular and renal protection Additional agents may include GLP-1 receptor agonists (e.g., semaglutide, dulaglutide) for weight loss and cardiovascular benefits, DPP-4 inhibitors (e.g., sitagliptin) as a weight-neutral option, sulfonylureas (e.g., gliclazide) to increase insulin secretion, or insulin therapy when other treatments prove insufficient Important medication interactions require attention
Outcomes vary depending on skin type, sun exposure, and maintenance
Society's been given some new tools for the latter, and now it's ever more important to focus on the former -- keeping that lean muscle